Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues.
Marcos NT, Bennett EP, Gomes J, Magalhaes A, Gomes C, David L, Dar I, Jeanneau C, DeFrees S, Krustrup D, Vogel LK, Kure EH, Burchell J, Taylor-Papadimitriou J, Clausen H, Mandel U, Reis CA. Marcos NT, et al. Among authors: kure eh. Front Biosci (Elite Ed). 2011 Jun 1;3(4):1443-55. doi: 10.2741/e345. Front Biosci (Elite Ed). 2011. PMID: 21622148 Free article.
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
Kjersem JB, Ikdahl T, Guren T, Skovlund E, Sorbye H, Hamfjord J, Pfeiffer P, Glimelius B, Kersten C, Solvang H, Tveit KM, Kure EH. Kjersem JB, et al. Among authors: kure eh. BMC Cancer. 2012 Nov 20;12:534. doi: 10.1186/1471-2407-12-534. BMC Cancer. 2012. PMID: 23167843 Free PMC article. Clinical Trial.
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH. Kjersem JB, et al. Among authors: kure eh. BMC Cancer. 2014 May 19;14:340. doi: 10.1186/1471-2407-14-340. BMC Cancer. 2014. PMID: 24884501 Free PMC article. Clinical Trial.
Molecular signatures of mRNAs and miRNAs as prognostic biomarkers in pancreatobiliary and intestinal types of periampullary adenocarcinomas.
Sandhu V, Bowitz Lothe IM, Labori KJ, Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J, Haaland T, Eide TJ, Børresen-Dale AL, Ikdahl T, Kure EH. Sandhu V, et al. Among authors: kure eh. Mol Oncol. 2015 Apr;9(4):758-71. doi: 10.1016/j.molonc.2014.12.002. Epub 2014 Dec 19. Mol Oncol. 2015. PMID: 25579086 Free PMC article.
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
Kjersem JB, Thomsen M, Guren T, Hamfjord J, Carlsson G, Gustavsson B, Ikdahl T, Indrebø G, Pfeiffer P, Lingjærde O, Tveit KM, Wettergren Y, Kure EH. Kjersem JB, et al. Among authors: kure eh. Pharmacogenomics J. 2016 Jun;16(3):272-9. doi: 10.1038/tpj.2015.54. Epub 2015 Aug 11. Pharmacogenomics J. 2016. PMID: 26261061
Differential expression of miRNAs in pancreatobiliary type of periampullary adenocarcinoma and its associated stroma.
Sandhu V, Bowitz Lothe IM, Labori KJ, Skrede ML, Hamfjord J, Dalsgaard AM, Buanes T, Dube G, Kale MM, Sawant S, Kulkarni-Kale U, Børresen-Dale AL, Lingjærde OC, Kure EH. Sandhu V, et al. Among authors: kure eh. Mol Oncol. 2016 Feb;10(2):303-16. doi: 10.1016/j.molonc.2015.10.011. Epub 2015 Nov 3. Mol Oncol. 2016. PMID: 26590090 Free PMC article.
72 results